His team consists of undergraduate researchers that utilize a variety of techniques, including: analytical chemistry, biotechnology, enzymology, structural biology, and synthetic chemistry. He uses structure-based drug design methodology to develop new classes of competitive inhibitors for enzyme drug-targets found in parasites of trypanosomatid diseases. These diseases include Chagas' disease (Trypanosoma cruzi), human African trypanosomiasis (Trypanosoma brucei), and leishmaniasis (Leishmania spp.). He has a focus on pentose phosphate pathway enzymes, which are known to be critically important for the survival of these parasites. Since human cells usually have similar enzymes of these drug-targets, our drug designs are created that give rise to parasite selectivity. Another goal of hisresearch is to optimize existing inhibitor designs by increasing molecular interactions within the inhibitor's binding site.